for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Penumbra Inc

PEN.N

Latest Trade

216.38USD

Change

-5.52(-2.49%)

Volume

251,877

Today's Range

211.30

 - 

223.06

52 Week Range

122.05

 - 

276.45

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
221.90
Open
223.06
Volume
251,877
3M AVG Volume
9.57
Today's High
223.06
Today's Low
211.30
52 Week High
276.45
52 Week Low
122.05
Shares Out (MIL)
36.31
Market Cap (MIL)
8,057.46
Forward P/E
-1,268.00
Dividend (Yield %)
--

Next Event

Q4 2020 Penumbra Inc Earnings Release

Latest Developments

More

Penumbra Posts Qtrly Loss Per Share $0.24

Penumbra Reports Second Quarter Results

Penumbra Inc Announces Pricing Of Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Penumbra Inc

Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.

Industry

Medical Equipment & Supplies

Contact Info

1 Penumbra

ALAMEDA, CA

94502-7676

United States

+1.510.9952486

http://www.penumbrainc.com/

Executive Leadership

Adam Elsesser

Chairman of the Board, Chief Executive Officer

Maggie S. Yuen

Chief Financial Officer

James Pray

President, International

Johanna Roberts

Executive Vice President, General Counsel, Secretary

Lynn D. Rothman

Executive Vice President, Chief Business Officer

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.4K

2019

0.5K

2020(E)

0.5K
EPS (USD)

2017

0.510

2018

0.510

2019

0.980

2020(E)

-0.175
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.96
Price To Book (MRQ)
12.94
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.62
LT Debt To Equity (MRQ)
4.40
Return on Investment (TTM)
-4.57
Return on Equity (TTM)
-3.96

Latest News

Latest News

BRIEF-Penumbra Inc Announces Pricing Of Offering Of Common Stock

* PENUMBRA, INC. ANNOUNCES PRICING OF OFFERING OF COMMON STOCK

BRIEF-Penumbra Launches Of Offering Of $100 Mln Of Common Shares

* PENUMBRA, INC. ANNOUNCES LAUNCH OF OFFERING OF $100,000,000 OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Penumbra Says Board Appointed Adam Elsesser As President

* PENUMBRA INC - BOARD APPOINTED ADAM ELSESSER AS PRESIDENT OF CO Source text: (https://bit.ly/2AiapTr) Further company coverage:

BRIEF-Penumbra Announces Management Transition

* PENUMBRA INC - SRI KOSARAJU WILL TRANSITION FROM HIS ROLE AS PRESIDENT Source text for Eikon: Further company coverage:

BRIEF-Penumbra Reports Quarterly Earnings Per Share Of $0.04

* PENUMBRA, INC. REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Penumbra Inc On April 24, Entered Into A Credit Agreement

* PENUMBRA INC - ON APRIL 24, ENTERED INTO A CREDIT AGREEMENT

BRIEF-Penumbra Says Withdraws Prior Annual Revenue Guidance For 2020 Due To COVID-19 Impact

* WITHDRAWS PRIOR ANNUAL REVENUE GUIDANCE FOR 2020 DUE TO COVID-19 IMPACT

BRIEF-Penumbra, Inc. Reports Qtrly Earnings Per Share $0.15

* PENUMBRA, INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Penumbra Inc Sees FY 2018 Revenue $400 Mln To $405 Mln

* PENUMBRA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Penumbra Announces Formation of Joint Venture, MVI Health

* PENUMBRA ANNOUNCES THE FORMATION OF JOINT VENTURE, MVI HEALTH

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up